Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | May 31, 2024 | June 04, 2024 |
| Inozyme Pharma, Inc.INZY · Entity 77717 | Director | October 03, 2024 | October 07, 2024 |
| Rezolute, Inc.RZLT · Entity 1990 | Director | November 19, 2025 | November 21, 2025 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | EVP & Chief Commercial Officer | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date May 31, 2024 · Filed June 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,052 |
Reported balance
After 2024-05-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-31 · Grant · Acquired 5,967 · Balance 17,052 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 9,402 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2034-05-31 | Direct | 17,901 |
Reported balance
After 2024-05-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-31 · Grant · Acquired 17,901 · Balance 17,901 F3: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 9,402 unvested RSUs.
F3: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Inozyme Pharma, Inc.
Report date October 03, 2024 · Filed October 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.06 · Expires 2034-10-02 | Direct | 56,000 |
Reported balance
After 2024-10-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-10-03 · Grant · Acquired 56,000 · Balance 56,000 F1: The option was granted on October 3, 2024. The shares underlying the option are scheduled to vest in equal monthly installments from October 3, 2024 through October 3, 2027 |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on October 3, 2024. The shares underlying the option are scheduled to vest in equal monthly installments from October 3, 2024 through October 3, 2027
Rezolute, Inc.
Report date November 19, 2025 · Filed November 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 21,000 |
Reported balance
After 2025-11-19 transaction · row 1
1 source rowRow 1 · 2025-11-19 · Grant · Acquired 21,000 · Balance 21,000 F1: Represents grant of restricted stock units which fully vest on December 1, 2026. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.16 · Expires 2035-11-19 | Direct | 12,000 |
Reported balance
After 2025-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-19 · Grant · Acquired 12,000 · Balance 12,000 F2: The options fully vest on December 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units which fully vest on December 1, 2026.
F2: The options fully vest on December 1, 2026.
Ultragenyx Pharmaceutical Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 118,410 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 28,895 · Balance 118,410 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.52 · Expires 2036-04-16 | Direct | 49,960 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 49,960 · Balance 49,960 F3: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 16, 2026 Filed Apr 20, 2026 21:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 49,960 | $0.00 Strike: $24.52 | $0.00 |
DisclosureSEC source: 0001193125-26-164267 · ownership.xml · derivative · entry 2 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,960 Underlying: Common Stock · 49,960 shares Expires 2036-04-16 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:13 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 28,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164267 · ownership.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,410 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 00:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 10,539 | $22.80 | $240,289.20 |
DisclosureSEC source: 0001193125-26-089282 · ownership.xml · nonDerivative · entry 2 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,515 F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range F4 · balance_after: Includes a total of 556 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025 and October 31, 2025. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 00:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 11,643 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-089282 · ownership.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,498 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:02 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001286 · form4.xml · derivative · entry 2 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:02 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001286 · form4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 F1 · shares: Represents grant of restricted stock units which fully vest on December 1, 2026. Read SEC document |
| March 25, 2025 Filed Mar 26, 2025 23:37 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0000912282-25-000333 · form4.xml · derivative · entry 1 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Shares · 60,000 shares Expires 2035-03-25 F1 · derivative.exercise_date: The options vest 1/36th monthly beginning in April 2025. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 15,103 | $42.10 | $635,836.30 |
DisclosureSEC source: 0000950170-25-032773 · ownership.xml · nonDerivative · entry 3 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,855 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes 539 shares acquired under the Company's Amended & Restated Employee Stock Purchase Plan on April 30, 2024 and October 31, 2024 F6 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 30,246 | $0.00 Strike: $42.92 | $0.00 |
DisclosureSEC source: 0000950170-25-032773 · ownership.xml · derivative · entry 4 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,246 Underlying: Common Stock · 30,246 shares Expires 2035-03-01 F7 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 18,443 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032773 · ownership.xml · nonDerivative · entry 2 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,419 F2 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 16,813 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032773 · ownership.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,976 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document |
| October 03, 2024 Filed Oct 7, 2024 16:37 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 56,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0000950170-24-113249 · ownership.xml · derivative · entry 1 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2034-10-02 F1 · derivative.exercise_date: The option was granted on October 3, 2024. The shares underlying the option are scheduled to vest in equal monthly installments from October 3, 2024 through October 3, 2027 Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 17,901 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001714899-24-000134 · wk-form4_1717540070.xml · derivative · entry 2 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,901 Underlying: Common Stock · 17,901 shares Expires 2034-05-31 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:27 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 5,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-24-000134 · wk-form4_1717540070.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,052 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 9,402 unvested RSUs. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 34,200 | $0.00 Strike: $53.69 | $0.00 |
DisclosureSEC source: 0000950170-24-026629 · ownership.xml · derivative · entry 4 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,200 Underlying: Common Stock · 34,200 shares Expires 2034-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,768 | $53.76 | $256,327.68 |
DisclosureSEC source: 0000950170-24-026629 · ownership.xml · nonDerivative · entry 3 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,163 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · balance_after: Includes 293 shares acquired under the Company's Amended & Restated Employee Stock Purchase Plan on October 31, 2023. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 957 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026629 · ownership.xml · nonDerivative · entry 2 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,638 F2 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:08 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 19,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026629 · ownership.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,681 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 6,000 | $37.96 | $227,760.00 |
DisclosureSEC source: 0001209191-23-048491 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,281 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.95 to $38.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 19, 2023 Filed Jun 21, 2023 22:17 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 305 | $48.20 | $14,701.00 |
DisclosureSEC source: 0001209191-23-038885 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,281 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 242 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 12,649 | $0.00 Strike: $30.92 | $0.00 |
DisclosureSEC source: 0001714899-23-000094 · wk-form4_1686002517.xml · derivative · entry 2 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,649 Underlying: Common Stock · 12,649 shares Expires 2033-06-01 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:02 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 4,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-23-000094 · wk-form4_1686002517.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,085 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 9,368 unvested RSUs. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 39,400 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-23-016039 · doc4.xml · derivative · entry 4 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,400 Underlying: Common Stock · 39,400 shares Expires 2033-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 3,664 | $45.25 | $165,796.00 |
DisclosureSEC source: 0001209191-23-016039 · doc4.xml · nonDerivative · entry 3 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,344 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · balance_after: Includes 185 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2022 F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016039 · doc4.xml · nonDerivative · entry 2 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,823 F2 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:51 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016039 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,823 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric. Read SEC document |
| June 19, 2022 Filed Jun 22, 2022 23:27 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 295 | $54.78 | $16,160.10 |
DisclosureSEC source: 0001209191-22-038774 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,160 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 138 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2022 F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:11 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 24,900 | $0.00 Strike: $67.37 | $0.00 |
DisclosureSEC source: 0001209191-22-015830 · doc4.xml · derivative · entry 3 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 24,900 shares Expires 2032-03-01 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:11 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015830 · doc4.xml · nonDerivative · entry 2 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,317 F2 · shares: Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:11 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,713 | $66.62 | $180,740.06 |
DisclosureSEC source: 0001209191-22-015830 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,317 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 23:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 20,607 | $0.00 Strike: $33.74 | $0.00 |
DisclosureSEC source: 0001714899-22-000024 · wf-form4_164427807583736.xml · derivative · entry 2 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,607 Underlying: Common Stock · 20,607 shares Expires 2032-02-03 F3 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 3, 2023, and an additional 1/48 of the shares subject to the option vest each month thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 23:54 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 6,869 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-22-000024 · wf-form4_164427807583736.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,869 F1 · security: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · deemedExecutionDate: 25% of the restricted stock units shall vest on February 3, 2023 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a non-employee director of the Issuer through each such date. Read SEC document |
| October 14, 2021 Filed Oct 18, 2021 22:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 303 | $81.14 | $24,585.42 |
DisclosureSEC source: 0001209191-21-060760 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,030 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 15:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 375 | $91.53 | $34,323.75 |
DisclosureSEC source: 0001209191-21-045972 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,333 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:55 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 572 | $94.96 | $54,317.12 |
DisclosureSEC source: 0001209191-21-042812 · doc4.xml · nonDerivative · entry 2 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,708 F2 · kind: The sales reported on the transaction date of June 21, 2021 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 19, 2021 Filed Jun 23, 2021 21:55 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 437 | $94.63 | $41,353.31 |
DisclosureSEC source: 0001209191-21-042812 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,280 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| May 07, 2021 Filed May 10, 2021 22:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 393 | $113.67 | $44,672.31 |
DisclosureSEC source: 0001209191-21-031378 · doc4.xml · nonDerivative · entry 2 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,717 F2 · kind: The sales reported on the transaction date of May 7, 2021 on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2021 Filed May 10, 2021 22:10 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 307 | $113.68 | $34,899.76 |
DisclosureSEC source: 0001209191-21-031378 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,110 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| April 20, 2021 Filed Apr 22, 2021 00:07 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 396 | $104.28 | $41,294.88 |
DisclosureSEC source: 0001209191-21-027881 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,417 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:42 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 707 | $138.16 | $97,679.12 |
DisclosureSEC source: 0001209191-21-017554 · doc4.xml · nonDerivative · entry 4 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,813 F5 · kind: The sales reported on this row were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:42 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $142.47 | $0.00 |
DisclosureSEC source: 0001209191-21-017554 · doc4.xml · derivative · entry 5 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-03-01 F7 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:42 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,470 | $138.17 | $341,279.90 |
DisclosureSEC source: 0001209191-21-017554 · doc4.xml · nonDerivative · entry 3 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,520 F3 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.16 to $138.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:42 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 4,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017554 · doc4.xml · nonDerivative · entry 2 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,990 F2 · shares: Represents 1,530 shares of common stock and 3,106 RSUs into which previously granted performance stock units were converted on March 1, 2021 upon certification of the performance metric. The RSUs will fully vest on March 1, 2022. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:42 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017554 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,354 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
| October 14, 2020 Filed Oct 16, 2020 23:20 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 220 | $88.00 | $19,360.00 |
DisclosureSEC source: 0001209191-20-055176 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,370 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 16:29 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 260 | $86.75 | $22,555.00 |
DisclosureSEC source: 0001209191-20-041641 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,590 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 19, 2020 Filed Jun 22, 2020 17:47 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 303 | $78.22 | $23,700.66 |
DisclosureSEC source: 0001209191-20-038111 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,850 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 03, 2020 Filed Feb 4, 2021 01:04 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,516 | $74.69 | $187,920.04 |
DisclosureSEC source: 0001209191-21-007555 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,854 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2020 Filed May 9, 2020 00:11 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 209 | $66.26 | $13,848.34 |
DisclosureSEC source: 0001209191-20-028117 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,153 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 19, 2020 Filed Apr 21, 2020 19:31 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 210 | $58.57 | $12,299.70 |
DisclosureSEC source: 0001209191-20-025186 · doc4.xml · nonDerivative · entry 1 Harris Erik · CIK 0001780113 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,362 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.